Repligen (NASDAQ:RGEN) Stock Price Down 4.8% – Here’s Why

Repligen Co. (NASDAQ:RGEN) was down 4.8% on Friday . The company traded as low as $133.33 and last traded at $135.54. Approximately 23,261 shares changed hands during mid-day trading, a decline of 96% from the average daily volume of 657,365 shares. The stock had previously closed at $142.43.

Wall Street Analyst Weigh In

Several research analysts have commented on RGEN shares. Benchmark reaffirmed a “hold” rating on shares of Repligen in a report on Monday, August 5th. StockNews.com raised Repligen from a “sell” rating to a “hold” rating in a research note on Wednesday. JPMorgan Chase & Co. upped their target price on Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a report on Wednesday, July 31st. Royal Bank of Canada restated an “outperform” rating and set a $205.00 price target on shares of Repligen in a report on Thursday, September 26th. Finally, Stephens reaffirmed an “overweight” rating and issued a $170.00 price objective on shares of Repligen in a research note on Tuesday, July 30th. Four investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $190.25.

Repligen Stock Down 12.4 %

The company has a market cap of $6.99 billion, a P/E ratio of -337.11, a price-to-earnings-growth ratio of 4.36 and a beta of 0.96. The firm’s 50 day moving average price is $141.09 and its two-hundred day moving average price is $144.48. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.56 and a current ratio of 6.65.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share for the quarter, beating the consensus estimate of $0.34 by $0.09. The firm had revenue of $154.87 million during the quarter, compared to the consensus estimate of $153.34 million. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.92%. The business’s revenue was up 9.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.23 earnings per share. Equities research analysts anticipate that Repligen Co. will post 1.44 EPS for the current fiscal year.

Insider Activity

In other Repligen news, Director Anthony Hunt sold 22,191 shares of the firm’s stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total value of $3,225,905.67. Following the transaction, the director now directly owns 139,840 shares of the company’s stock, valued at approximately $20,328,540.80. This trade represents a 13.70 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 1.20% of the company’s stock.

Institutional Investors Weigh In On Repligen

Institutional investors and hedge funds have recently made changes to their positions in the business. Andra AP fonden acquired a new position in Repligen during the 2nd quarter valued at about $25,000. International Assets Investment Management LLC purchased a new position in shares of Repligen during the second quarter valued at approximately $33,000. UMB Bank n.a. grew its holdings in Repligen by 138.3% during the third quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company’s stock worth $33,000 after buying an additional 130 shares in the last quarter. Lazard Asset Management LLC grew its holdings in Repligen by 206.1% during the first quarter. Lazard Asset Management LLC now owns 202 shares of the biotechnology company’s stock worth $36,000 after buying an additional 136 shares in the last quarter. Finally, Blue Trust Inc. raised its position in Repligen by 113.4% in the 3rd quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company’s stock valued at $36,000 after buying an additional 127 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.